These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34211709)

  • 21. Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants.
    Spratt AN; Kannan SR; Woods LT; Weisman GA; Quinn TP; Lorson CL; Sönnerborg A; Byrareddy SN; Singh K
    Comput Struct Biotechnol J; 2021; 19():3799-3809. PubMed ID: 34188776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective.
    Ibrahim IM; Elfiky AA; Elgohary AM
    Biochem Biophys Res Commun; 2021 Jul; 562():89-93. PubMed ID: 34049205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic.
    Li X; Zhang L; Chen S; Ji W; Li C; Ren L
    Infect Genet Evol; 2021 Sep; 93():104971. PubMed ID: 34146731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
    Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
    Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
    Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A
    Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H.
    Zeng C; Evans JP; Faraone JN; Qu P; Zheng YM; Saif L; Oltz EM; Lozanski G; Gumina RJ; Liu SL
    mBio; 2021 Oct; 12(5):e0251021. PubMed ID: 34607452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2.
    Yoshimoto FK
    Protein J; 2021 Jun; 40(3):260-295. PubMed ID: 33629236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Spike Protein Mutations in the Infectious Power of SARS-COV-2 Variants: A Molecular Interaction Perspective.
    Gómez SA; Rojas-Valencia N; Gómez S; Cappelli C; Restrepo A
    Chembiochem; 2022 Apr; 23(7):e202100393. PubMed ID: 34529328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Mutational Pattern in the Fourth Pandemic Phase in Greece.
    Halvatsiotis P; Vassiliu S; Koulouvaris P; Chatzantonaki K; Asonitis K; Charvalos E; Siatelis A; Houhoula D
    Curr Issues Mol Biol; 2022 Jan; 44(1):329-335. PubMed ID: 35723403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the Interaction between E484K and N501Y Substitutions of SARS-CoV-2 in Shaping the Transmission Advantage of COVID-19 in Brazil: A Modeling Study.
    Zhao S; Ran J; Han L
    Am J Trop Med Hyg; 2021 Sep; 105(5):1247-1254. PubMed ID: 34583340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Lambda (C.37): An emerging variant of concern?
    Darvishi M; Rahimi F; Talebi Bezmin Abadi A
    Gene Rep; 2021 Dec; 25():101378. PubMed ID: 34632160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants.
    Gellenoncourt S; Saunders N; Robinot R; Auguste L; Rajah MM; Kervevan J; Jeger-Madiot R; Staropoli I; Planchais C; Mouquet H; Buchrieser J; Schwartz O; Chakrabarti LA
    J Virol; 2022 Oct; 96(19):e0130122. PubMed ID: 36121299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Analysis of SARS-CoV-2 Circulating in Bangladesh during 2020 Revealed Lineage Diversity and Potential Mutations.
    Parvin R; Afrin SZ; Begum JA; Ahmed S; Nooruzzaman M; Chowdhury EH; Pohlmann A; Paul SK
    Microorganisms; 2021 May; 9(5):. PubMed ID: 34065789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of the Novel Mutations in the SARS-CoV-2 Genome for Transmission, Disease Severity, and the Vaccine Development.
    Akkiz H
    Front Med (Lausanne); 2021; 8():636532. PubMed ID: 34026780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations.
    Cocherie T; Zafilaza K; Leducq V; Marot S; Calvez V; Marcelin AG; Todesco E
    Microorganisms; 2022 Dec; 11(1):. PubMed ID: 36677322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases.
    Nayak B; Lal G; Kumar S; Das CJ; Saraya A; Shalimar
    Front Cell Infect Microbiol; 2021; 11():753249. PubMed ID: 34760721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal-Geographical Dispersion of SARS-CoV-2 Spike Glycoprotein Variant Lineages and Their Functional Prediction Using
    Boon SS; Xia C; Wang MH; Yip KL; Luk HY; Li S; Ng RWY; Lai CKC; Chan PKS; Chen Z
    mBio; 2021 Oct; 12(5):e0268721. PubMed ID: 34700382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
    Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
    Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.